"Sharing the Latest RNA Therapeutic Technologies"... ST Pharm Successfully Concludes RISC 2026

Nobel Laureate Craig Mello and Other Global RNA Leaders Gather at One Event

ST Pharm announced on September 14 that it successfully concluded the international symposium on RNA innovation, "RISC 2026," which was held at the Yangjae EL Tower in Seocho-gu, Seoul on September 8, with over 300 domestic and international participants from academia, industry, and research institutes in attendance.

RISC is an international symposium organized by ST Pharm to share the latest research achievements and industry trends in the field of RNA therapeutics and to expand global collaborations among academia, industry, and research institutions.

This year marked the second edition of the event, following 2024. Professor Craig Mello of UMass Chan Medical School in the U.S., who won the 2006 Nobel Prize in Physiology or Medicine for his research on RNA interference (RNAi), delivered the keynote speech.

Professor Mello explained that RNAi is not only a technology for suppressing the expression of specific genes but also a fundamental biological system in which cells recognize, monitor, and regulate genetic information. He further emphasized the importance of research in this field, noting that RNA-based information networks mediated by small RNAs and proteins play a critical role in genome stability and overall life phenomena.

This symposium covered major RNA therapeutic modalities such as small interfering RNA (siRNA), microRNA (miRNA), and messenger RNA (mRNA), as well as a variety of next-generation delivery technologies, including antibody oligonucleotide conjugates (AOC) and peptide-based targeted delivery technologies (POC).

An ST Pharm representative stated, "We will continue to expand collaboration with global researchers and companies through RISC so that innovations in basic science can be linked to new drug development and industrialization."

This content was produced with the assistance of AI translation services.